AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36253717 — intervention group
Group type: COMPARATOR
Intervention: Normal saline + propofol (Group C)
Number of subjects: 59
Study 32539596 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 0
Study 32539596 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic/pharmacodynamic studies
Number of subjects: 0
Study 32303364 — intervention group
Group type: EXPERIMENTAL
Intervention: Worked examples with hints (video or text)
Number of subjects: 147
Study 32303364 — intervention group
Group type: COMPARATOR
Intervention: Worked examples without hints (video or text)
Number of subjects: 147
Study 35230203 — intervention group
Group type: EXPERIMENTAL
Intervention: ThePaS-I (Therapy Program for Adequate Sexual Behaviors Version 1) - offending-specific skills training
Number of subjects: 0
Study 35230203 — intervention group
Group type: EXPERIMENTAL
Intervention: ThePaS-II (Therapy Program for Adequate Sexual Behaviors Version 2) - general socioemotional skills training
Number of subjects: 0
Study 35576438 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaglenastat plus Everolimus (TelaE)
Number of subjects: 69
Study 35576438 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Everolimus (PboE)
Number of subjects: 69
Study 33287911 — intervention group
Group type: EXPERIMENTAL
Intervention: Human albumin 20% (60-g loading dose over 2–3 h, followed by 40–80 g infusion to maintain serum levels at least 30 g/l for 28 days)
Number of subjects: 1412
Study 33287911 — intervention group
Group type: COMPARATOR
Intervention: Usual practice with crystalloids for resuscitation and maintenance
Number of subjects: 1412
Study 37563249 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse collection (venepuncture and DBS)
Number of subjects: 2162
Study 37563249 — intervention group
Group type: COMPARATOR
Intervention: Self-collection (DBS)
Number of subjects: 2162
Study 37563249 — intervention group
Group type: COMPARATOR
Intervention: Nurse collection (venepuncture)
Number of subjects: 2162
Study 33969923 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine nasal spray
Number of subjects: 304
Study 33969923 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 304
Study 33327551 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic training (IHT)
Number of subjects: 30
Study 33327551 — intervention group
Group type: COMPARATOR
Intervention: Control group (normoxic conditions)
Number of subjects: 30
Study 36429591 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided mAPA
Number of subjects: 37
Study 36429591 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person mAPA
Number of subjects: 37
Study 36429591 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 37
Study 32348832 — intervention group
Group type: EXPERIMENTAL
Intervention: Closer adherence to a Mediterranean diet (aMedi tertile 3)
Number of subjects: 7756
Study 32348832 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish consumption (quartile 4)
Number of subjects: 7756
Study 34038293 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT + lifestyle education program
Number of subjects: 41
Study 34038293 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 41
Study 33197659 — intervention group
Group type: EXPERIMENTAL
Intervention: Buteyko training (BG)
Number of subjects: 32
Study 33197659 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 32
Study 32362175 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized text message support and a checklist for initiation of antihypertensive medication
Number of subjects: 111
Study 32362175 — intervention group
Group type: COMPARATOR
Intervention: Control group (no personalized text message support and checklist)
Number of subjects: 111
Study 33928209 — intervention group
Group type: EXPERIMENTAL
Intervention: Study regimen targeting aberrant pathway (veliparib with temozolomide, adavosertib with carboplatin, everolimus, or trametinib)
Number of subjects: 69
Study 33928209 — intervention group
Group type: COMPARATOR
Intervention: Control regimen not targeting aberrant pathway (one of the same four regimens)
Number of subjects: 69
Study 32667223 — intervention group
Group type: EXPERIMENTAL
Intervention: Paediatric Autism Communication Therapy
Number of subjects: 18
Study 35579410 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (n=15)
Number of subjects: 30
Study 35579410 — intervention group
Group type: COMPARATOR
Intervention: Diode laser (n=15)
Number of subjects: 30
Study 33746043 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual family-centered rounds (FCR) plus standard of care
Number of subjects: 110
Study 33746043 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 110
Study 32227566 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation by an African American second‐year genetic counseling student with a brochure detailing the same information (presentation group)
Number of subjects: 90
Study 32227566 — intervention group
Group type: COMPARATOR
Intervention: Brochure only (brochure group)
Number of subjects: 90
Study 32227566 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 36448506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixation of ulnar styloid fractures (Group A)
Number of subjects: 43
Study 36448506 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment of ulnar styloid fractures (Group B)
Number of subjects: 43
Study 33651442 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral TXA 250 mg bid
Number of subjects: 45
Study 33651442 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/mL intradermal TXA
Number of subjects: 45
Study 33651442 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/mL intradermal TXA
Number of subjects: 45
Study 33177272 — intervention group
Group type: EXPERIMENTAL
Intervention: UCLP group
Number of subjects: 30
Study 33177272 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 32976087 — intervention group
Group type: EXPERIMENTAL
Intervention: High Attributional Training (AT)
Number of subjects: 144
Study 32976087 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Attributional Training (AT)
Number of subjects: 144
Study 32976087 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 144
Study 34113408 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular multimodal cocktail injection with betamethasone (7 mg)
Number of subjects: 60
Study 34113408 — intervention group
Group type: COMPARATOR
Intervention: Periarticular multimodal cocktail injection without corticosteroids
Number of subjects: 60
Study 32990618 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient-fortified salt
Number of subjects: 228
Study 32990618 — intervention group
Group type: COMPARATOR
Intervention: Control (no fortified salt)
Number of subjects: 228
Study 35561011 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led medication adherence therapy (MAT)
Number of subjects: 85
Study 35561011 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 85
Study 33966891 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 221
Study 33966891 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCA) with morphine
Number of subjects: 221
Study 33966891 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA
Number of subjects: 221
Study 33966891 — intervention group
Group type: COMPARATOR
Intervention: PCA
Number of subjects: 221
Study 36055465 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong opioid (step 3 of the WHO ladder)
Number of subjects: 153
Study 36055465 — intervention group
Group type: COMPARATOR
Intervention: Weak opioid (step 2 of the WHO ladder)
Number of subjects: 153
Study 32994107 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous presentation of three options (no test, 5-gene, 15-gene)
Number of subjects: 454
Study 32994107 — intervention group
Group type: COMPARATOR
Intervention: Sequential presentation of options (no test, 5-gene, then 15-gene)
Number of subjects: 454
Study 32994107 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporating a provider recommendation
Number of subjects: 454
Study 35831058 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI+PGT‐A
Number of subjects: 450
Study 35831058 — intervention group
Group type: COMPARATOR
Intervention: ICSI
Number of subjects: 450
Study 34967191 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised dietary guidance and anti-resistance exercise (Group C)
Number of subjects: 78
Study 34967191 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised dietary guidance (Group B)
Number of subjects: 78
Study 34967191 — intervention group
Group type: COMPARATOR
Intervention: Educational seminars (Group A)
Number of subjects: 78
Study 34967191 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and comprehensive groups (Group B and C)
Number of subjects: 78
Study 33849683 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine 2.5 mg
Number of subjects: 32
Study 33849683 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine 5 mg
Number of subjects: 32
Study 33849683 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine 10 mg
Number of subjects: 32
Study 33849683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 33968874 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based Muscle Strengthening Exercise (COME) program
Number of subjects: 32
Study 32807157 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive peer mentor intervention plus usual care
Number of subjects: 12
Study 32807157 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 12
Study 35689521 — intervention group
Group type: EXPERIMENTAL
Intervention: VYC‐17.5L
Number of subjects: 15
Study 35689521 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 15
Study 33387550 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen plus IANB using 2% lidocaine with 27 μg clonidine
Number of subjects: 62
Study 33387550 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide/oxygen plus IANB using 2% lidocaine with 18 μg epinephrine
Number of subjects: 62
Study 33387550 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 62
Study 33387550 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 62
Study 33578597 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 minutes rest group
Number of subjects: 79
Study 33578597 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 minute 45 seconds rest group
Number of subjects: 79
Study 33578597 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 minute 30 seconds rest group
Number of subjects: 79
Study 33578597 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 79
Study 32421513 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video
Number of subjects: 79
Study 32421513 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 79
Study 35276883 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented group (GS)
Number of subjects: 24
Study 35276883 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (GP)
Number of subjects: 24
Study 35276883 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 35276883 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 24
Study 33448402 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (medium anti-NP, 145-299 OD units)
Number of subjects: 39
Study 33448402 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (high anti-NP, ≥300 OD units)
Number of subjects: 39
Study 33448402 — intervention group
Group type: COMPARATOR
Intervention: Control plasma
Number of subjects: 39
Study 32026389 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol (UMEC/VI) 62.5/25 mcg
Number of subjects: 148
Study 32026389 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium/olodaterol (TIO/OLO) 5/5 mcg
Number of subjects: 148
Study 33556765 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop algorithm (CLA) for DBS programming
Number of subjects: 12
Study 33556765 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) for DBS programming
Number of subjects: 12
Study 32552784 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated disease management (IDM)
Number of subjects: 1086
Study 32552784 — intervention group
Group type: COMPARATOR
Intervention: Usual care (guideline-supported non-programmatic care)
Number of subjects: 1086
Study 34338165 — intervention group
Group type: EXPERIMENTAL
Intervention: SMArT intervention
Number of subjects: 107
Study 32726445 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher relative abundances of Megasphaera species type 1
Number of subjects: 0
Study 32726445 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher relative abundances of Megasphaera species type 2
Number of subjects: 0
Study 32726445 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher relative abundances of Mageeibacillus indolicus
Number of subjects: 0
Study 32726445 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher relative abundances of Bifidobacterium bifidum
Number of subjects: 0
Study 32726445 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher relative abundances of Aerococcus christensenii
Number of subjects: 0
Study 32726445 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher relative abundances of Lactobacillus mucosae
Number of subjects: 0
Study 32726445 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher relative abundances of Streptococcus equinus/infantarius/lutentiensis
Number of subjects: 0
Study 32726445 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher relative abundances of Prevotella bivia
Number of subjects: 0
Study 32726445 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher relative abundances of Dialister propionicifaciens
Number of subjects: 0
Study 32726445 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher relative abundances of Lactobacillus crispatus/helveticus
Number of subjects: 0
Study 32726445 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing quantities of Megasphaera species
Number of subjects: 0
Study 32726445 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing quantities of M indolicus
Number of subjects: 0
Study 32726445 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing quantities of L crispatus
Number of subjects: 0
Study 33291206 — intervention group
Group type: EXPERIMENTAL
Intervention: Portfolio assessment system
Number of subjects: 7
Study 33291206 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized objective assessment procedures
Number of subjects: 7
Study 35300357 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-session pharmacist-led intervention focusing on modifiable psychosocial factors
Number of subjects: 31
Study 35300357 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-session pharmacist-led intervention
Number of subjects: 31
Study 35300357 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 31
Study 32467299 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT + IL-2
Number of subjects: 44
Study 32467299 — intervention group
Group type: COMPARATOR
Intervention: IL-2 monotherapy
Number of subjects: 44
Study 32467299 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover group (SBRT + IL-2)
Number of subjects: 44
Study 36410471 — intervention group
Group type: EXPERIMENTAL
Intervention: Ripasudil-brimonidine fixed-dose combination (RBFC)
Number of subjects: 488
Study 36410471 — intervention group
Group type: COMPARATOR
Intervention: Ripasudil
Number of subjects: 488
Study 36410471 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine
Number of subjects: 488
Study 33481829 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi training for 6 months
Number of subjects: 87
Study 33481829 — intervention group
Group type: COMPARATOR
Intervention: Tai Chi experts
Number of subjects: 87
Study 33481829 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive dual-task walking
Number of subjects: 87
Study 35227729 — intervention group
Group type: EXPERIMENTAL
Intervention: Contracted endodontic cavity (CEC)
Number of subjects: 48
Study 35227729 — intervention group
Group type: COMPARATOR
Intervention: Traditional endodontic cavity (TEC)
Number of subjects: 48
Study 32278578 — intervention group
Group type: EXPERIMENTAL
Intervention: Double layer bandage
Number of subjects: 93
Study 32278578 — intervention group
Group type: COMPARATOR
Intervention: Crepe bandage
Number of subjects: 93
Study 34447181 — intervention group
Group type: EXPERIMENTAL
Intervention: aceclofenac + paracetamol
Number of subjects: 150
Study 34447181 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac tromethamine
Number of subjects: 150
Study 34447181 — intervention group
Group type: EXPERIMENTAL
Intervention: lornoxicam + paracetamol
Number of subjects: 150
Study 34447181 — intervention group
Group type: EXPERIMENTAL
Intervention: tramadol + paracetamol
Number of subjects: 150
Study 34447181 — intervention group
Group type: EXPERIMENTAL
Intervention: paracetamol
Number of subjects: 150
Study 33228727 — intervention group
Group type: EXPERIMENTAL
Intervention: CPB/DHCA + HA380 hemoperfusion
Number of subjects: 88
Study 33228727 — intervention group
Group type: COMPARATOR
Intervention: CPB/DHCA only (control group)
Number of subjects: 88
Study 33035972 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal exposure to NO2
Number of subjects: 39782
Study 33035972 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal PM10 and NO2
Number of subjects: 39782
Study 33035972 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal outdoor temperature
Number of subjects: 39782
Study 33035972 — intervention group
Group type: EXPERIMENTAL
Intervention: Perinatal and current dampness, indoor mould, and cockroaches
Number of subjects: 39782
Study 33035972 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal exposure to farm environment and large family size
Number of subjects: 39782
Study 33035972 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical emissions from indoor materials after first year of life
Number of subjects: 39782
Study 32417298 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully covered self-expanding metal stents (FCSEMSs)
Number of subjects: 41
Study 35853748 — intervention group
Group type: EXPERIMENTAL
Intervention: Goals-of-care decision aid (DA)
Number of subjects: 66
Study 35853748 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no intervention)
Number of subjects: 66
Study 33548020 — intervention group
Group type: EXPERIMENTAL
Intervention: As-needed budesonide-formoterol 200/6 μg
Number of subjects: 3366
Study 33548020 — intervention group
Group type: COMPARATOR
Intervention: Maintenance budesonide 200 μg
Number of subjects: 3366
Study 33548020 — intervention group
Group type: COMPARATOR
Intervention: As-needed terbutaline 0.5 mg
Number of subjects: 3366
Study 36443750 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined less dense laser and intra vitreal bevacizumab (IVB) treatment
Number of subjects: 43
Study 36443750 — intervention group
Group type: COMPARATOR
Intervention: Conventional laser therapy
Number of subjects: 43
Study 33954780 — intervention group
Group type: EXPERIMENTAL
Intervention: HPHF meal (60 g protein, 40 g fat)
Number of subjects: 10
Study 33954780 — intervention group
Group type: COMPARATOR
Intervention: LPLF meal (5 g protein, 5 g fat)
Number of subjects: 10
Study 33954780 — intervention group
Group type: EXPERIMENTAL
Intervention: HPHF meal (0 to 2 hours)
Number of subjects: 10
Study 33954780 — intervention group
Group type: EXPERIMENTAL
Intervention: HPHF meal (2 to 4 hours)
Number of subjects: 10
Study 33954780 — intervention group
Group type: EXPERIMENTAL
Intervention: HPHF meal (4 to 5 hours)
Number of subjects: 10
Study 32661604 — intervention group
Group type: EXPERIMENTAL
Intervention: Total confinement (TC)
Number of subjects: 156
Study 32661604 — intervention group
Group type: COMPARATOR
Intervention: Partial confinement (PC)
Number of subjects: 156
Study 36474942 — intervention group
Group type: EXPERIMENTAL
Intervention: Online patient decision aid with individualized potential outcomes of surgery
Number of subjects: 163
Study 36474942 — intervention group
Group type: COMPARATOR
Intervention: Control group (no decision aid)
Number of subjects: 163
Study 33793018 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical intervention (ES) - tonsillectomy with or without adenoidectomy and turbinate reduction
Number of subjects: 114
Study 33793018 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting (WW)
Number of subjects: 114
Study 32349513 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Thai foot massage (STFM)
Number of subjects: 25
Study 32349513 — intervention group
Group type: COMPARATOR
Intervention: Thai foot massage (TFM)
Number of subjects: 25
Study 35028756 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam
Number of subjects: 30
Study 35028756 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 30
Study 33094438 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP)
Number of subjects: 814
Study 33094438 — intervention group
Group type: COMPARATOR
Intervention: Deceptive placebo (DP)
Number of subjects: 814
Study 35750246 — intervention group
Group type: EXPERIMENTAL
Intervention: PM condition (afternoon)
Number of subjects: 32
Study 35750246 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity group
Number of subjects: 32
Study 35750246 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-weight group
Number of subjects: 32
Study 35750246 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity group in the evening condition
Number of subjects: 32
Study 34602729 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine, butorphanol, and propofol (DBP)
Number of subjects: 0
Study 34602729 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam, butorphanol, and propofol (MBP)
Number of subjects: 0
Study 35398558 — intervention group
Group type: EXPERIMENTAL
Intervention: Acculturation (measured by the Short Acculturation Scale for Hispanics)
Number of subjects: 167
Study 35398558 — intervention group
Group type: COMPARATOR
Intervention: Acculturation (Spanish-speaking vs English-speaking)
Number of subjects: 167
Study 35398558 — intervention group
Group type: EXPERIMENTAL
Intervention: Acculturation (greater levels)
Number of subjects: 167